Previous 10 | Next 10 |
Cytosorbents (NASDAQ:CTSO) is scheduled to announce Q4 earnings results on Tuesday, March 8th, after market close. The consensus EPS Estimate is -$0.13 and the consensus Revenue Estimate is $10.8M Over the last 3 months, EPS estimates have seen 2 upward revisions and 1 downward. Revenue estim...
The following slide deck was published by Cytosorbents Corporation in conjunction with this event. For further details see: Cytosorbents (CTSO) Presents At Annual SVB Leerink Global Health Conference
CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results PR Newswire MONMOUTH JUNCTION, N.J. , Feb. 8, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions i...
CytoSorbents Announces Participation in Two Upcoming Virtual Investor Conferences PR Newswire MONMOUTH JUNCTION, N.J. , Feb. 3, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the inten...
CytoSorbents (NASDAQ:CTSO) said the first patient was enrolled in the PROCYSS trial evaluating CYtoSorb to reverse refractory septic shock (RSS). RSS is a persistent and potentially fatal drop in blood pressure despite fluid resuscitation and high dose vasopressor use, seen in patients with l...
First Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb® to Restore Hemodynamic Stability in Patients with Refractory Septic Shock PR Newswire MONMOUTH JUNCTION, N.J. , Feb. 1, 2022 /PRNewswire/ -- CytoSorbents C...
New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents' Antithrombotic Drug Removal Technology PR Newswire MONMOUTH JUNCTION, N.J. , Jan. 24, 2022 /PRNewswire/ --...
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue Preliminary Full Year 2021 Product Sales were approximately $40.1 million, including core non-COVID-19 sales growth of approximately 13% from 2020. Cumulative CytoSorb treatm...
CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular PR Newswire MONMOUTH JUNCTION, N.J. , Dec. 21, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threa...
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO) PR Newswire MONMOUTH JUNCTION, N.J. , Dec. 20, 2021 /PRNewswire/ -- CytoSorbents Cor...
News, Short Squeeze, Breakout and More Instantly...
CytoSorbents Corporation Company Name:
CTSO Stock Symbol:
NASDAQ Market:
CytoSorbents Corporation Website:
PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that it has regained comp...
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of ...
PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces it will present...